Genotyping of CYP2C19 with Allele Specific Fluorescent Polymerase Chain Reaction

Chang-sheng XIA,Chang LIU,Yuan-yuan SUN,Yan LONG,Xiao-tao ZHAO
DOI: https://doi.org/10.16352/j.issn.1001-6325.2013.03.014
2013-01-01
Abstract:Objective To explore the distribution of CYP2C19 genotype in the population and evaluate the method of allele specific fluorescent polymerase chain reaction(PCR) for CYP2C19 genotyping.Methods Peripheral blood specimens were collected from 356 donors.The techniques of allele specific fluorescent PCR and gold standard DNA direct sequencing were used for CYP2C19 genotyping with a blind synchro-method.Results PCR assay detected 46.6%(166/356) CYP2C19*1/*1 types,33.2%(118/356) CYP2C19*1/*2 types,10.7%(38/356) CYP2C19*2/*2 types,2.0%(7/356) CYP2C19*2/*3 types,0.8%(3/356) CYP2C19*3/*3 types,and 6.7%(24/356) CYP2C19*1/*3 types.DNA sequencing detected 46.3%(165/356) CYP2C19*1/*1 types,33.4%(119/356) CYP2C19*1/*2 types,11.0%(39/356) CYP2C19*2/*2 types,2.0%(7/356) CYP2C19*2/*3 types,0.8%(3/356) CYP2C19*3/*3 types,and 6.5%(23/356) CYP2C19*1/*3 types.The coincidence rate was 99.2% for genotyping results by two methods.Conclusions CYP2C19 genotype testing is required in the clinical laboratory for the medication safety;fluorescent PCR assay for CYP2C19 genotyping is a feasible technology.
What problem does this paper attempt to address?